Administration of Tadalafil in Patients With Benign Prostatic Hyperplasia
Status:
COMPLETED
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The aim of the present study is to evaluate the efficacy and safety of once daily administration PDE5 inhibitors, tadalafil for 3 months as anti-inflammatory, antiproliferative and relaxant effects in ED with BPH patients.